RDY vs VTRS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: VTRS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. RDY and VTRS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined RDY and VTRS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Dr. Reddy's Laboratories, founded in 1984 and based in Hyderabad, India, is one of the largest Indian pharmaceutical companies, spanning active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter products. Its therapeutic focus areas include gastrointestinal, cardiovascular, diabetes, oncology, pain management, and dermatology, and its major markets are the United States, India, Russia and CIS, Europe, and emerging markets. The US generics arm (Dr. Reddy's Laboratories, Inc., based in Princeton, New Jersey) is the single largest revenue contributor, and the company trades on the NYSE as an American Depositary Receipt (ADR) while also listing in India.

Full RDY guide

Viatris was created in November 2020 by merging Mylan with Pfizer's Upjohn business, uniting a large generics and biosimilars operation with a portfolio of well-known, off-patent branded drugs such as Lipitor, Norvasc, Viagra, and EpiPen. It sells across more than 165 countries and reports through a global commercial footprint that spans developed and emerging markets, with a business mix of generics, established brands, and a smaller but growing specialty and pipeline component. Because most of its revenue comes from mature, off-patent medicines, Viatris behaves like a value stock: steady cash generation, a modest valuation multiple, and slow top-line growth rather than the rapid expansion of a patent-protected innovator.

Full VTRS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• RDY drivers: Biosimilars ramp; GLP-1 / semaglutide opportunity.
• VTRS drivers: Cash flow, debt reduction, and the dividend; Pivot from generics giant to specialty and pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The loss of generic Revlimid exclusivity in early 2026 removed a large, high-margin profit stream, and Q4 FY26 showed the impact: revenue fell about 11.6% year over year and gross margin dropped to roughly 44.8% from about 55.6% a year earlier. For VTRS, the biggest risk is structural: most of Viatris's revenue comes from mature, off-patent medicines facing constant price erosion and competition, which has produced years of flat-to-declining sales and makes growth hard to generate.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick RDY if you believe its drivers more; VTRS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the RDY and VTRS guides.

RDY. FY2026 (year ended March 31, 2026) revenue was about 335,933 million rupees (roughly $4.0 billion), up about 3.2%, but Q4 profit before tax collapsed to about 2.6% of revenue as the Revlimid exclusivity ended and margins compressed. The stock trades around a mid-20s price-to-earnings multiple with a low payout ratio (near 15%) and a modest sub-1% dividend yield. Figures are approximate, converted from Indian rupee reporting, and can shift with exchange rates and each quarterly release.

VTRS. Figures are approximate and tied to the asOf date; verify live numbers (current revenue, guidance, adjusted and GAAP EPS, dividend, and debt levels) before acting. Viatris trades on a low multiple typical of a slow-growth value stock, and its adjusted EPS looks much healthier than its GAAP result because large non-cash impairments hit the reported bottom line. The gap between adjusted and GAAP earnings, plus how much of the low multiple reflects genuine value versus stagnant revenue, is the crux of the debate on the stock.

Headline figures (approximate, July 2026): RDY shows revenue (fy26) ~$4.0B, market cap ~$12.8B, p/e (normalized) ~27x, fy26 ebitda margin ~22.8%; VTRS shows revenue (fy2025) ~$13.9 to $14.3 billion, down from ~$14.7 billion in 2024, partly due to divestitures, fy2026 revenue guidance ~$14.45 to $14.95 billion (reaffirmed), fy2026 adjusted eps guidance ~$2.33 to $2.47, fy2025 gaap result Large net loss (~$3.5 billion) driven mainly by non-cash goodwill impairment.

RDY and VTRS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined RDY and VTRS exposure against your real portfolio. It is not an investment adviser.